Abstract
Background: The antidiabetic effects of the gut hormone xenin include augmenting insulin secretion and positively affecting pancreatic islet architecture. Methods: The current study has further probed pancreatic effects through sub-chronic administration of the long-acting xenin analogue, xenin-25[Lys 13PAL], in both high fat fed (HFF) and streptozotocin (STZ)-induced insulin-deficient Ins1 Cre/+;Rosa26-eYFP transgenic mice. Parallel effects on metabolic control and pancreatic islet morphology, including islet beta-cell lineage tracing were also assessed. Results: Xenin-25[Lys 13PAL] treatment reversed body weight loss induced by STZ, increased plasma insulin and decreased blood glucose levels. There were less obvious effects on these parameters in HFF mice, but all xenin-25[Lys 13PAL] treated mice exhibited decreased pancreatic alpha-cell areas and circulating glucagon. Xenin-25[Lys 13PAL] treatment fully, or partially, returned overall islet and beta-cell areas in STZ- and HFF mice to those of lean control animals, respectively, and was consistently associated with decreased beta-cell apoptosis. Interestingly, xenin-25[Lys 13PAL] also increased beta-cell proliferation and decreased alpha-cell apoptosis in STZ mice, with reduced alpha-cell growth noted in HFF mice. Lineage tracing studies revealed that xenin-25[Lys 13PAL] reduced the number of insulin positive pancreatic islet cells that lost their beta-cell identity, in keeping with a decreased transition of insulin positive to glucagon positive cells. These beneficial effects on islet cell differentiation were linked to maintained expression of Pdx1 within beta-cells. Xenin-25[Lys 13PAL] treatment was also associated with increased numbers of smaller sized islets in both models. Conclusions: Benefits of xenin-25[Lys 13PAL] on diabetes includes positive modulation of islet cell differentiation, in addition to promoting beta-cell growth and survival.
| Original language | English |
|---|---|
| Article number | e3384 |
| Pages (from-to) | 1-10 |
| Number of pages | 10 |
| Journal | Diabetes/Metabolism Research and Reviews |
| Volume | 37 |
| Issue number | 3 |
| Early online date | 13 Jul 2020 |
| DOIs | |
| Publication status | Published (in print/issue) - 31 Mar 2021 |
Bibliographical note
Funding information: Department for the Economy, Northern Ireland; Invest Northern Ireland; European Foundation for the Study of Diabetes; Diabetes UKFunding
Department for the Economy, Northern Ireland; Invest Northern Ireland; European Foundation for the Study of Diabetes; Diabetes UK
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- xenin
- high fat fed
- streptozotocin
- Xenin; h beta-cell dedifferentiation
- islet
- Ins1Cre/+;Rosa26-eYFP mice
- Ins1 ;Rosa26-eYFP mice
- beta-cell dedifferentiation
Fingerprint
Dive into the research topics of 'Enzymatically stable analogue of the gut-derived peptide xenin on beta-cell transdifferentiation in high fat fed and insulin-deficient Ins1Cre/+;Rosa26-eYFP mice'. Together they form a unique fingerprint.Profiles
-
Victor Gault
- Faculty Of Life & Health Sciences - Associate Dean (Research and Innovation)
Person: Academic
-
Nigel Irwin
- School of Pharm. & Pharmaceut. Sc. - Professor
- Faculty Of Life & Health Sciences - Full Professor
- Biomedical Sciences Research
Person: Academic
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver